This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Shipping:
Room Temperature Shipping
Tibosovo (ivosidenib) is shipped under controlled room temperature conditions (15°C to 25°C). Certified medical couriers maintain consistent handling standards to preserve product quality during delivery.
Disease Indications:
• Acute Myeloid Leukemia (AML)
• Cholangiocarcinoma (Bile Duct Cancer)
Manufacturer:
Agios Pharmaceuticals, Inc.
Usage:
Oral
Tibosovo (ivosidenib)
General Description:
Tibosovo (ivosidenib) is an oral prescription medicine for adults with cancers that have an IDH1 mutation. It is used to treat:
• Acute Myeloid Leukemia (AML) that is newly diagnosed or relapsed/refractory
• Locally advanced or metastatic bile duct cancer (cholangiocarcinoma)
Tibosovo works by blocking the abnormal IDH1 enzyme, which drives the growth of certain cancer cells. By inhibiting this enzyme, the medicine helps slow disease progression and support normal cell development.
The treatment is taken orally under the supervision of a qualified oncologist. Dosage and treatment duration are tailored to the patient’s condition and response to therapy.
Getting Tibosovo (ivosidenib) in India
Tibosovo is approved by leading global regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). While it may not yet be widely available in India, patients can obtain Tibosovo through a Named Patient Program (NPP) under medical supervision.
MitoGENE assists Indian patients in accessing Tibosovo safely and in full compliance with national regulations. The team manages all documentation, import permissions, and logistics to ensure a secure and transparent process focused on patient care.
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
Available Dosage Form & Package:
• Tablets – 60 tablets of 250 mg each
How to Access Tibosovo (ivosidenib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Tibosovo (ivosidenib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
